Discover how tirzepatide, a first‑in‑class dual GIP/GLP‑1 “twincretin,” delivers up to ~20% body weight reduction, improves cardiometabolic risk factors, and bridges the gap between obesity pharmacotherapy and metabolic surgery.
Discover how tirzepatide, a dual GIP and GLP‑1 receptor agonist, is transforming obesity and type 2 diabetes care with surgery‑rivaling weight loss, powerful glycemic control, and better metabolic health compared with traditional weight‑loss drugs.